🇺🇸 Lubiprostone 24 in United States
2 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 2
Most-reported reactions
- Abdominal Pain — 1 report (50%)
- Faecal Incontinence — 1 report (50%)
Other Gastroenterology approved in United States
Frequently asked questions
Is Lubiprostone 24 approved in United States?
Lubiprostone 24 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Lubiprostone 24 in United States?
Sucampo Pharma Americas, LLC is the originator. The local marketing authorisation holder may differ — check the official source linked above.